Alnylam Pharmaceuticals vs Medpace Holdings
Alnylam Pharmaceuticals (ALNY), health care, and Medpace Holdings (MEDP), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Alnylam Pharmaceuticals is worth $21B on the stock market and Medpace Holdings $18.3B: Alnylam Pharmaceuticals is valued at 15% more. Alnylam Pharmaceuticals trades at 7.9 times earnings and Medpace Holdings at 36.3; operating margins in their latest fiscal years were 13.5% and 21.1%. Over the past year Alnylam Pharmaceuticals's share price has moved -65.4% and Medpace Holdings's +9.83%.
Key facts
- Alnylam Pharmaceuticals market value
- $21B
- Medpace Holdings market value
- $18.3B
- Alnylam Pharmaceuticals P/E
- 7.9
- Medpace Holdings P/E
- 36.3
- Alnylam Pharmaceuticals revenue
- $3.7BFY to 2025-12-31
- Medpace Holdings revenue
- $2.5BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Alnylam Pharmaceuticals | Medpace Holdings |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $21Bhigher | $18.3Blower |
| Revenue | $3.7Bhigher | $2.5Blower |
| Earnings | $313.7Mlower | $451.1Mhigher |
| Employees | 2,500lower | 6,600higher |
| Total assets | $5Bhigher | $2Blower |
| Valuation | ||
| P/E | 7.9lower | 36.3higher |
| P/S | 5.6lower | 7.2higher |
| P/B | 5.8lower | 31.2higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 13.5%lower | 21.1%higher |
| Balance sheet | ||
| Net assets | $789.2Mhigher | $459.1Mlower |
| Total liabilities | $4.2Bhigher | $1.5Blower |
| Total debt | — | — |
| Cash on hand | $1.7Bhigher | $497Mlower |
| Price change | ||
| Today | -2.02%lower | +0.75%higher |
| 1 year | -65.4%lower | +9.83%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Baillie Gifford team1.3% / 0.3%
Alnylam Pharmaceuticals only (3)
Medpace Holdings only (6)
- François Rochon5.2%
- C.T. Fitzpatrick1.4%
- Mairs & Power team0.5%
- Jim Simons (1938–2024)0.4%
- Cliff Asness0.2%
- Terry Smith0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Alnylam Pharmaceuticals / Medpace Holdings). Who owns ALNY · Who owns MEDP
More on Alnylam Pharmaceuticals
Further comparisons
Alnylam Pharmaceuticals against its closest peers
Medpace Holdings against its closest peers
Learn
Questions and answers
Which is bigger, Alnylam Pharmaceuticals or Medpace Holdings?
By market value, Alnylam Pharmaceuticals is the larger: $21B against $18.3B for Medpace Holdings. By revenue in its latest fiscal year, Alnylam Pharmaceuticals is the larger: $3.7B against $2.5B for Medpace Holdings.
Which has the higher P/E ratio?
Medpace Holdings: 36.3, against 7.9 for Alnylam Pharmaceuticals. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Medpace Holdings: 21.1%, against 13.5% for Alnylam Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Alnylam Pharmaceuticals and Medpace Holdings?
In their latest 13F filings, Baillie Gifford team holds both.
Cite this page
Funkfolio, “Alnylam Pharmaceuticals vs Medpace Holdings”, data as of 18 November 2026. https://funkfolio.com/compare/alny-vs-medp
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.